Spero Therapeutics Announces Positive Phase 3 Clinical Trial Results From ADAPT-PO
On August 8, Spero Therapeutics, Inc. (SPRO) announced positive topline results from its Phase 3 clinical trial. The ADAPT-PO clinical trial evaluates Spero’s oral antibiotic candidate tebipenem HBr for the treatment of complicated urinary tract (cUTI) infection and acute pyelonephritis (AP) in adults. The results showed that Spero’s oral treatment was statistically non-inferior to intravenous (IV) ertapenem treatments. This is the first ever trial of an entirely oral treatment for patients with cUTI.
Sonal detected the event and sent an alert at 7:30 am. The next trade took place at 9:30 am for $9.17. Spero’s stock price had steady gains throughout the day before closing at $13.07. That makes an event-day gain of 40.4%.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!